During the past decade, Lysosomal and Rare Disorders Research and Treatment Center, Inc. conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lysosomal and Rare Disorders Research and Treatment Center, Inc." #1 sponsor was "Amicus Therapeutics" with 5 trials, followed by "Lysosomal and Rare Disorders Research and Treatment Center, Inc." with 4 trials sponsored, "ADMA Biologics, Inc." with 2 trials sponsored, "Green Cross Corporation" with 1 trials sponsored and "Homology Medicines, Inc" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lysosomal and Rare Disorders Research and Treatment Center, Inc." #1 collaborator was "Atlantic Research Group" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Lysosomal and Rare Disorders Research and Treatment Center, Inc." are "Fabry Disease" (3 trials), "Gaucher Disease" (2 trials), "Lysosomal Storage Diseases" (2 trials), "Pompe Disease (Late-onset)" (2 trials) and "Fabry Disease, Cardiac Variant" (1 trials). Many other conditions were trialed in "Lysosomal and Rare Disorders Research and Treatment Center, Inc." in a lesser frequency.

Most popular intervention types in "Lysosomal and Rare Disorders Research and Treatment Center, Inc." are "Biological" (7 trials), "Drug" (5 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "AT2221" (2 trials), "ATB200" (2 trials), "Bivigam" (2 trials), "migalastat HCl 150 mg" (2 trials) and "Cipaglucosidase Alfa" (1 trials). Other intervention names were less common.

The vast majority of trials in "Lysosomal and Rare Disorders Research and Treatment Center, Inc." are 14 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Lysosomal and Rare Disorders Research and Treatment Center, Inc.". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 1 completed trials in Lysosomal and Rare Disorders Research and Treatment Center, Inc., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Lysosomal and Rare Disorders Research and Treatment Center, Inc., 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".